Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05488470 · ClinicalTrials.gov registry record
QT Changes as Detected From LINQ ECG During Antiarrhythmic Loading (LINQ QT)
A clinical trial, sponsored by Medtronic Cardiac Rhythm and Heart Failure.
- Completed
- Registry status
- 22
- Enrollment target
NCT05488470: Completed study, sponsored by Medtronic Cardiac Rhythm and Heart Failure.
NCT05488470 is a clinical trial that has completed, run by Medtronic Cardiac Rhythm and Heart Failure. The registered enrollment target is 22 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05488470 has completed, sponsored by Medtronic Cardiac Rhythm and Heart Failure.
- COMPLETED
- Registry status
- 22 participants
- Enrollment target
Study Summary
The LINQ QT Study is a prospective, non-randomized, multi-center, observational, post-market clinical study investigating QT interval changes due to antiarrhythmic drug loading.
Primary Outcome
The QT intervals during antiarrhythmic loading will be compared for all patients with available LINQ ECG from the baseline anti arrhythmic loading hospitalization to analyze QT changes that may be caused due to antiarrhythmic drugs.
Interventions
- DEVICE LINQ/LINQ II
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2023-02-20 |
| Est. Completion | 2024-07-23 |
What the finished NCT05488470 record still lists
NCT05488470 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 22 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which LINQ/LINQ II is the first listed.
NCT05488470 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05488470 about?
NCT05488470 is a clinical study titled "QT Changes as Detected From LINQ ECG During Antiarrhythmic Loading (LINQ QT)". The LINQ QT Study is a prospective, non-randomized, multi-center, observational, post-market clinical study investigating QT interval changes due to antiarrhythmic drug loading.
What is the current status of trial NCT05488470?
This trial is currently completed. The enrollment target is 22 participants. The study started on 2023-02-20. Estimated completion is 2024-07-23.
What interventions are being tested in trial NCT05488470?
The interventions under investigation include: LINQ/LINQ II (DEVICE).
Who is sponsoring clinical trial NCT05488470?
This trial is sponsored by Medtronic Cardiac Rhythm and Heart Failure, which has 115 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02508038 · 22 participants · Phase 1
Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors
- NCT03099356 · 22 participants · Phase 2
Cyclophosphamide and Sirolimus for the Treatment of Metastatic, RAI-refractory, Differentiated Thyroid Cancer
- NCT03676647 · 22 participants
Diagnostic DNA Methylation Signature in Diagnosing Thyroid Cancer After Fine-Needle Aspiration in Patients With Thyroid Nodules
- NCT04569591 · 22 participants · NA
DDAVP for Pituitary Adenoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI